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Patients with brain and other central nervous system cancers experience debilitating
physical, cognitive, and emotional effects, which significantly compromise quality of life.
Few efficacious pharmacological strategies or supportive care interventions exist to ameliorate these sequelae and patients report high levels of unmet needs in these areas. There
is strong theoretical rationale to suggest exercise may be an effective intervention to aid
in the management of neuro-oncological disorders. Clinical research has established the
efficacy of appropriate exercise in counteracting physical impairments such as fatigue and
functional decline, cognitive impairment, as well as psychological effects including depression and anxiety. While there is promise for exercise to enhance physical and psychosocial
wellbeing of patients diagnosed with neurologic malignancies, these patients have unique
needs and research is urgently required to explore optimal exercise prescription specific
to these patients to maximize safety and efficacy. This perspective article is a discussion
of potential rehabilitative effects of targeted exercise programs for patients with brain and
other central nervous system cancers and highlights future research directions.
Keywords: exercise, physical activity, brain tumor, brain metastases, cancer

INTRODUCTION
Malignant brain tumors and other central nervous system cancers
(referred to as brain cancer hereafter) represent a highly challenging and devastating group of cancers. While the incidence of brain
cancer is relatively low, mortality is high with the most recently
reported 5-year survival rates at ~19–35% in Australia, United
Kingdom, and America (1–3). Median survival varies with tumor
pathology, grade, and demographic factors with older patients who
have higher grade cancer and poor performance status faced with
the worst prognosis of only limited months of survival (4). Not
only does brain cancer have one of the lowest survival rates but it
is also one of the leading sites contributing to burden of disease
caused by cancer (1). Brain cancer patients experience debilitating
physical, cognitive, and emotional effects, which significantly compromise quality of life (QOL) both for patients and their families
(5, 6). The profound effect on physical and mental function leads
to a premature loss of independence and significant economic burden both at the individual and societal level (7–9). This concern
is accentuated by the fact that brain cancer is not just a disease of
the elderly but occurs across all age groups, commonly affecting
patients at the peak of their work and child-rearing responsibilities (average age of diagnosis is 57 years; ~65% of diagnoses occur
at 45–84 years) (10). This paper focuses on the adult rather than
pediatric setting.
At diagnosis, patients with brain cancer frequently experience
neurological deficits including impaired balance, motor skills,
and vision as well as headaches, seizures, and cognitive declines
including memory and/or speech loss (11). In addition to tumor
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symptoms, treatment itself is associated with a range of toxicities.
Treatment modalities include surgery, radiation, chemotherapy,
and corticosteroids, alone and in combination (12). Some of the
most troublesome adverse effects associated with these treatments
include fatigue, myopathy, impairments in physical functioning,
insomnia, additional cognitive decline, mood disturbance, and
psychological distress (6, 13–20). Frequently used anticonvulsant
medications may further accentuate fatigue and somnolence experienced by patients (21). As a consequence, patients are often
unable to continue working and cannot legally drive. These issues
combine to significantly compromise QOL (5). Currently, there
are few established pharmacological strategies, which may ameliorate the debilitating effects associated with brain cancer and
its treatment. Thus, not only do patients experience high symptom burden but also the symptoms are difficult to treat and based
on the dearth of established management therapies may not be
addressed. This is highlighted by the level of unmet supportive
care needs among patients and their caregivers (22–24). Clearly,
there is a pressing need to discover viable management options to
counteract the incapacitating effects of brain cancer and address
the unique needs of these patients. In this article, we discuss the
potential of exercise as one such option.

EXERCISE TO COUNTERACT PHYSICAL EFFECTS OF BRAIN
CANCER
Brain cancer patients experience considerable physical impairments that compromise QOL and independence. The average level
of fatigue experienced by these patients is ~40–50% more severe
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than normative levels for cancer patients, equating to approximately five times the clinically meaningful difference (25–29).
Markedly reduced strength and fitness capabilities compared to
age- and sex-matched norms have also been reported (26). Specifically, maximal muscular strength was observed to be 57 ± 28%
of predicted values and cardiorespiratory fitness reported to be
41 ± 10% of predicted values among clinically stable patients following surgery (26). Functional capacity as assessed by the 6-min
walk test has also been reported to be compromised in brain cancer
patients, corresponding to 56 ± 13% of age- and sex-matched normative values (25). Notably, these data were collected in relatively
well patients with good performance status (i.e., ≥70% Karnofsky performance status) and as such the degree of impairment
for more debilitated patients is expected to be further compromised. Unfavorable changes in body composition are also apparent
with a loss of lean mass and gains in fat mass evident following
surgery (26). Additionally, while fatigue and somnolence are evident, insomnia is also commonly experienced by patients with
brain cancer at higher rates than the general population (30).
To date, there have been no clinical trials evaluating the efficacy
of exercise in counteracting the physical impairments experienced
by brain cancer patients. However, clinical research has established
the beneficial effect of exercise in ameliorating many of these
impairments in other cancer populations. Specifically, appropriate exercise prescription has been shown to reduce cancer-related
fatigue (31), enhance strength, fitness, and common functional
movements (e.g., ambulation, chair rise, and stair climb ability)
(32–35), promote favorable changes in body composition (i.e.,
increased lean mass and reduced fat mass) (33–35), and improve
sleep quality (36). While these data were not specifically obtained
from brain cancer patients, they provide strong theoretical rationale for the potential beneficial effect of exercise in these patients.
As of November 2014, there were no clinical trials registered in
Australia, USA, or Europe, exploring the possible role of exercise
in managing the side effects of brain cancer in adults. However, two small exercise intervention trials enrolling children with
brain cancer have been recently launched in USA (NCT01944761,
NCT02000986). Our team has been conducting pilot work to
determine the feasibility and safety of exercise in adult grade
III/IV glioma patients with initial observations suggesting that
well-designed and appropriately supervised exercise may help to
counteract many of the adverse physical side effects. To date,
eight well-functioning (Eastern Cooperative Oncology Group performance status of 0–1) patients with high grade glioma have
completed an exercise program involving three supervised exercise
sessions weekly for the duration of chemoradiotherapy (~7 weeks)
and are continuing with an additional 7 weeks of the exercise program after completing radiation therapy. Participants tolerated
the exercise program well with no adverse events occurring during the exercise sessions and only one patient withdrawing due to
time constraints. Despite intensive concurrent treatment, attendance was high at 87% and the average perceived exertion was in
line with the target for people with cancer (13.4 ± 1.0 on the Borg
6–20 rating of perceived exertion scale; target = 12–16). Initial
observations include 20 ± 16% improvement in muscle strength,
9 ± 10% improvement in cardiorespiratory fitness, and enhanced
functional ability with improvements of 12 ± 7% in ambulation,
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7 ± 11% in chair rise ability, and 12 ± 17% in dynamic balance.
While only a short intervention period, favorable body composition changes were also observed with a 1.0 ± 2.4% average increase
in lean muscle mass and varying results for changes in fat mass
depending on whether or not patients were receiving dexamethasone (loss of 6 ± 6 vs. gain of 12 ± 12% fat mass in patients
not receiving and receiving dexamethasone, respectively). Future
research is needed to expand on this very early pilot work by
exploring the efficacy of appropriately prescribed and supervised
exercise for brain cancer patients in randomized controlled trials.
Early results convey that dexamethasone use may be a relevant
stratification factor and may require consideration in exercise prescription given the sequela of weight gain and proximal myopathy
(37). It will also be important to investigate the potential role of
exercise in patients with poorer performance status given the high
demand for improving existing deficits and preventing further
declines in physical functioning.

EXERCISE TO COUNTERACT COGNITIVE EFFECTS OF BRAIN
CANCER
Few patients avoid experiencing impairments in cognitive function associated with brain cancer (38–40). While the etiology and
degree of impairment varies, declines commonly occur in memory, attention, executive function, verbal fluency, and visuospatial
perception (39, 40). Such deficiencies significantly compromise
QOL through adversely impacting daily activities and interpersonal relationships (41, 42). Impact on the carer and other family
members’ QOL is considerable especially given the subsequent
reductions in independence (39–42). While pharmacological and
cognitive rehabilitation interventions have been proposed and
show promising evidence, the management of cognitive effects
caused by brain cancer and its treatment remains a major challenge
(22, 43–45).
The potential role of exercise in attenuating such cognitive
impairments has not been evaluated in brain cancer patients.
However, a robust body of literature involving animal models as
well as various patient models of healthy aging and other diseases associated with impaired cognition (e.g., Alzheimer’s disease,
stroke) has established the efficacy of exercise as a potent therapy for maintaining and improving cognitive function (46–50).
Exercise has a neuroprotective effect, reducing the risk of cognitive decline during aging as well as the incidence of dementia
and Alzheimer’s disease (46–50). The vast majority of longitudinal research also indicates exercise is an effective intervention
for improving cognitive function in cognitively healthy adults
(46–50). Importantly, exercise has been observed to be particularly beneficial in reversing deficits among patients with cognitive
impairments, resulting in improved cognitive function across a
variety of domains (46–50). Findings from one of the first investigations specific to cancer suggest that exercise may also help
counteract cognitive impairments caused by chemotherapy agents
(based on an animal model of colorectal cancer) (51). A considerable body of literature including neuroimaging, human, and
animal studies outside the cancer setting has elucidated the main
mechanisms believed to be responsible for the preventative and
restorative effects of exercise on cognition (52–55). Specifically,
exercise mechanistically drives improvements in brain function
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and structure through stimulating neurogenesis and neural plasticity, up-regulating growth factors including brain-derived neurotropic factor, reducing levels of endogenous corticosteroids and
pro-inflammatory cytokines, reducing oxidative stress, preserving brain volume, improving vascularization and increasing blood
flow throughout the central nervous system, and increasing levels
of hormones beneficial to neural structure and function (52–
55). Despite clear differences in the pathophysiology of cognitive
declines experienced by brain cancer patients, this establishes exercise as a promising intervention to counteract the cognitive effects
experienced by patients.
Currently, there are a handful of registered trials evaluating the potential of exercise to prevent or rehabilitate cognitive
impairments in cancer patients. The only investigation specifically involving people with brain cancer was recently opened
in USA (NCT02153957) and will determine whether exercise
improves cognitive problems in children treated with radiation at least 2 years prior to enrollment in the study. There
are also two trials being conducted in adults with breast cancer; one led by our team exploring whether exercising during
treatment prevents chemotherapy-induced cognitive impairment
(ACTRN12614000051640) and the other ongoing in Canada
investigating if exercise can improve cognitive dysfunction following the completion of chemotherapy (NCT01296893). While the
results of these trials are pending, it is clear that specific research
is required to evaluate the effects of exercise on cognitive function
in patients with brain cancer. Based on evidence from other populations, future research should assess objective outcome measures
of cognitive function including formal neurocognitive function
testing, imaging studies, and self-report performance indicators
from both patients and their carers. It would be beneficial to
examine if exercise can delay onset and/or worsening of cognitive
impairments as well as alleviate established deficiencies.

EXERCISE TO COUNTERACT EMOTIONAL EFFECTS OF BRAIN
CANCER
The diagnosis and treatment of brain cancer is undoubtedly a
distressing experience, which has significant impact on psychosocial wellbeing (6, 20). There is a high prevalence of moderate to
severe depression and anxiety among this patient group (20). In
fact, the prevalence and severity of depression, anxiety, and overall emotional distress in people with brain cancer are consistently
among the highest experienced for any cancer site (56). Beyond
these well-defined disorders, patients experience a range of additional emotional challenges including existential issues, loss of
self-identity, fear of and guilt about burden imposed on carers,
stress, worry, uncertainty, loneliness, and a sense of waiting for
cancer progression/death (57–60). The emotional effects of brain
cancer extend to carers who also experience considerable declines
in psychosocial wellbeing (61). Not surprisingly, the resulting negative impact on QOL is indeed significant (6, 62). Clearly, the
psychosocial morbidity caused by brain cancer is profound and
leads to a complex suite of supportive care needs for both patients
and care-givers (63).
While there is a paucity of research investigating the potential of exercise in counteracting the emotional issues associated
with brain cancer, there is clear evidence to suggest a potential
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therapeutic benefit. Most notably, exercise is recognized as a treatment option for the management of clinical depression by major
psychological societies internationally (64, 65). These recommendations are informed by a series of meta-analyses establishing a
significant positive effect of exercise in reducing depressive symptoms in adults without cancer (66–70). The efficacy of exercise
in managing the psychological distress experienced by cancer
patients has also been reported, with meta-analyses confirming
the beneficial impact of exercise extends to people with cancer
(71–73). A relatively small but statistically significant reduction in
psychological symptoms has been observed although larger effects
were reported for exercise programs that were supervised, clinic
based, and involved a greater volume of exercise (71). Notably, the
majority of participants were within the normal range on depression scales, raising the potential of more pronounced effects in
distressed patients. The impact of exercise on other components
of psychosocial wellbeing is rarely evaluated in existing literature
but qualitative research provides evidence of considerable benefit
across a range of psychosocial elements (74).
An interrelated group of biopsychosocial factors are theorized to be driving these exercise-induced improvements.
Physiologically, exercise elicits favorable adaptations in endorphins, monoamine neurotransmitters (e.g., serotonin, dopamine
and norepinephrine), neurotropic growth factors, inflammatory
cytokines, and corticosteroids (47, 75–77). Additionally, specific
exercise produces acute surges in testosterone in men and women,
a powerful anabolic hormone with considerable non-genomic
effects on the nervous system including reduced depression and
anxiety (78–80). Furthermore, superior functional status is associated with lower depressive symptomology in brain cancer patients
(81, 82), suggesting that exercise may also alleviate psychological
distress by preserving physical capabilities and functional independence. There is a range of psychosocial factors that may also
contribute including improved self-efficacy, social support provided by instructors, and peers involved with the exercise program
and the potential of exercise to act as a distraction from negative thoughts (74, 83). Moreover, exercise is an intervention that
patients have control of and it is possible that involvement in
a structured exercise program may represent an opportunity to
empower patients in dealing with the emotional impact of brain
cancer (74).
Future research investigating the efficacy of exercise in counteracting the psychosocial morbidity associated with brain cancer
is warranted for both patients and their carers. The potential complementary effect of exercise, psychological, and pharmacological
interventions in counteracting these emotional problems poses an
exciting avenue for novel research and superior clinical practice.

EXERCISE AND SURVIVAL
Higher performance status is a well-established prognostic factor
in brain cancer, which is associated with better survival outcomes (4, 84). Given this relationship, it would seem intuitive
that greater levels of exercise may also confer a protective effect
against brain cancer progression and epidemiological evidence
has suggested such an effect (85). Specifically, patients with brain
cancer who achieved a greater volume of weekly aerobic exercise
had a significantly reduced risk of mortality compared to those
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who exercise less (hazard ratio 0.64; 95% confidence intervals
0.46–0.91; p < 0.001) (85). This effect was independent of a range
of prognostic factors including age, sex, grade, number of prior
progressions, and performance status (85). The mechanisms driving this protective effect are unclear, but may involve a range of
physiological adaptations that modulate tumor progression (86)
and/or an enhanced ability to tolerate greater dosages of adjuvant
treatment (87). However, it is possible that patients with superior exercise behavior have lower symptomology and as such these
observations may reflect reverse causality rather than a physiological effect (85). While future research is required to elucidate
the mechanisms, these data add to a growing body of literature
reporting that exercise reduces the risk of cancer mortality in
other patient groups (88–91). Additionally, it has been recently
reported that increased aerobic exercise levels are associated with
a reduced risk of fatal brain cancer (multivariate adjusted hazard ratio 0.58; 95% confidence intervals 0.35–0.95; p = 0.030),
raising the hypothesis that exercise may also protect against the
development of brain cancer (92).

IMPLICATIONS FOR PRACTICE
Exercise shows promise as a supportive care intervention to counteract the adverse impact of brain cancer. Despite their poor
prognosis, a relatively high proportion of brain cancer patients
participate in exercise throughout (59%) and after (69%) anticancer treatments (93). Furthermore, 60 and 76% of brain cancer
patients are open to receiving information about exercise, and 66
and 91% of patients believe they may be able to participate in an
exercise program during and after treatment respectively (94). In
the absence of any brain cancer specific data, health professionals
should rely on the current guidelines for all cancer patients when
providing exercise advice to this group (95, 96). These guidelines
recommend patients avoid inactivity even when undergoing difficult treatments and aim to participate in regular aerobic (e.g.,
walking, cycling) and resistance (i.e., lifting weights) exercise. To
realize significant health benefits, patients should perform at least
150 min of moderate intensity aerobic exercise and two to three
moderate intensity resistance exercise sessions weekly (95, 96).
Decades of exercise science research have demonstrated that the
quality of the exercise program, especially in terms of the mode,
intensity, and volume of exercise, moderates the type and magnitude of adaptations in a dose-response fashion. Given this coupled
with the complexity of physiological and psychological impairments common to people with brain cancer, sophisticated exercise
prescription and monitoring are required. As such, referral to a
clinical exercise physiologist is strongly recommended to ensure
an appropriate exercise prescription that maximizes safety and
patient benefits.

CONCLUSION
There is strong theoretical rationale to suggest that exercise
may be an effective intervention to aid in the management
of brain cancer symptoms and treatment side effects. Clinical
research has established the efficacy of appropriate exercise in
counteracting physical impairments such as fatigue and functional decline, cognitive impairment, as well as psychological
effects including depression and anxiety, within other cancer

Frontiers in Oncology | Neuro-Oncology

Role of exercise in neuro-oncology

patients and chronic disease populations. This is supported by
promising early evidence and clinical observations in brain cancer patients, but more research is required to explore optimal exercise prescription specific to the unique needs of these
patients in order to maximize safety and efficacy. The potential
rehabilitative effect of targeted exercise interventions in neurooncology is exciting, especially given that exercise represents a
relatively inexpensive and highly accessible intervention that has
very few adverse side-effects when appropriately prescribed and
supervised.
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